How has been the historical performance of Krebs Biochem?

Answer:The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years. Breakdown: Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar'21 to 169.04 Cr in Mar'25, while shareholder's funds have deteriorated, showing a negative value of -146.24 Cr in Mar'25. The cash flow from operating activities has remained negative, indicating ongoing financial challenges. Overall, Krebs Biochem's financial performance has been characterized by declining revenues, increasing losses, and deteriorating equity over the years.